Strong Semi Momentum Drives 1H21 Beat for Frencken; BUY
Frencken (SGX:E28)'s 1H21 PATMI rose 67.2% y-o-y to S$31.3m, surpassing our and consensus’ estimates. This was driven by stronger-than-expected semicon momentum and robust recovery in automotive.
We raise FY21-23E EPS by 6-15%, and our target price is now based on 15.5x FY22E P/E (from 14.5x FY21E) as we believe:
cyclicality risks have moderated; and
margin expansion trend remains on track.
We believe key risk is components shortages worsening in the various supply chains Frencken is exposed to.
Maintain BUY.
Automotive Segment Drove Frencken's Margin Expansion in 1H21
Frencken's 1H21 revenue rose 28.3% y-o-y to S$375.3m, largely on the back of semicon (+60.2% y-o-y) and automotive (+40.3% y-o-y) strength. Frencken registered growth with all semicon customers, from the front-end to the back-end. Medical (+11.5% y-o-y) benefitted from the return of elective surgeries, while Analytical (+29.4%) recovered as a key customer’s products saw a rebound following some challenges last year.
On the recovery of the automotive segment, gross margin expanded by 1.9ppt y-o-y to 17.4% on the recovery of the automotive segment, while the integrated manufacturing services segment margins swung 12.5ppt y-o-y to 11%.
Frencken's 2H21 Revenue Likely
Frencken expects side tightness can be alleviated. Meanwhile, the medical and analytical segments are expected to enjoy sequential strength. Industrial automation (IA) should be softer h-o-h.
We See Reduced Cyclicality Risks for Frencken
We raise FY21-23E EPS by reduced cyclicality as we expect semiconductor strength to be sustained in the next 1-2 years, while other end-markets continue their post-COVID-19 recovery.
Key upside to our forecast is if there is lumpy capex from IA customer Seagate.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....